Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesA. Michael Lincoff, Donna H. Ryan, Kirstine Brown‐Frandsen et al.|New England Journal of Medicine|2023Cited by 2.6k
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trialRichard E. Pratley, Adie Viljoen, Vanita R. Aroda et al.|The Lancet Diabetes & Endocrinology|2018Cited by 758
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical TrialAndrew Ahmann, Vanita R. Aroda, Francesco Dotta et al.|Diabetes Care|2017Cited by 574
Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversationIldiko Lingvay, Carel W. le Roux, Priya Sumithran et al.|The Lancet|2021Cited by 555
Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 TrialHelena W. Rodbard, Е. О. Филиппова, Julio Rosenstock et al.|Diabetes Care|2019Cited by 442